New drug aimed at treating and preventing Mesothelioma – OSI-930
OSI -930 is an orally active inhibitor. It has been designed to target cancer cell proliferation and new blood vessel growth in certain tumours, by inhibiting the receptor, the pathway that is believed to be the single most important mechanism for recruitment of new blood vessels.
Drug researchers, Simcere Pharmaceutical Group, based in China and OSI Pharmaceuticals in the US have agreed to base the research for the Kit Inhibitor in China. The drug has shown positive results in treating various lung cancers and therefore the proposed treatment of Mesothelioma by using this drug is being investigated.
Mesothelioma is a rare form of lung cancer that is mainly caused by exposure to asbestos. The asbestos fibres when breathed in are lodged in the membrane lining of the lungs and other organs. Over the course of many years the fibres interfere with the cells development which then leads to the onset of Mesothelioma. Due to the long lag time between exposure and development of Mesothelioma victims often have a very limited life expectancy. This is mainly due to the location of the cancer on the surface of the lung and the fact that it does not respond very well to chemotherapy.
Phase 1 which was carried out on healthy volunteers has been completed and Phase 1 being carried out on cancer patients is currently ongoing. Should the drug prove to be successful those suffering from the fatal disease could face a new outlook in the treatment available. Useful info: